The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1267 articles
After semaglutide's patent expired on March 20, over 40 Indian manufacturers launched 50+ generics, slashing prices up to 90%. Novo Nordisk, maker of Ozempic and Wegovy, is countering not with deep discounts but clinical data from 50+ trials and partnerships. Vikrant Shrotriya shares how this strategy aims to widen access while preserving quality.
India's government is ramping up enforcement against GLP-1 drug misuse following a flood of cheap semaglutide generics. Inspections at 49 pharmacies, wholesalers, and clinics uncovered unauthorized sales and misleading marketing. With sales surging 177%, regulators warn of health risks without medical supervision.
Weight loss drugs like Ozempic are transforming bodies, but dentists are sounding the alarm on 'Ozempic teeth'—a pattern of dry mouth, tooth sensitivity, and gum problems. Lt. Gen Dr Vimal Arora of Clove Dental notes increased xerostomia, dental caries, and early periodontal inflammation among users. Discover why this happens and steps to safeguard your smile.
GLP-1 therapies, including Ozempic (semaglutide) and Mounjaro (tirzepatide), have evolved from diabetes treatments to versatile options for weight management and cardiovascular health. While offering significant benefits like reduced appetite and vascular protection, they come with gastrointestinal side effects and rare serious risks. This guide evaluates their risks and rewards across conditions.
At a recent Pune meeting, experts from Pune and Mumbai underscored a holistic framework for Semaglutide use in weight management, especially as the drug goes off-patent in India. They stress pairing it with diet, exercise, and thorough patient assessments for lasting results in obesity and diabetes control. Generic versions now available for Rs 1,290 per month offer affordable access with proper precautions.
If Tirzepatide worked initially but now you've hit a plateau, it's not failure—it's metabolic adaptation signaling the next phase. California Trim Clinic is leading the shift to retatrutide, a triple-pathway therapy targeting energy expenditure for sustained results. Patients are moving beyond plateaus with physician-guided care.
Telangana's Drugs Control Administration has issued a stark warning against misusing Semaglutide formulations for weight loss without medical oversight. With patent expiry looming in March 2026, multiple versions are flooding the market, raising safety concerns. Improper use risks serious complications like pancreatitis and gastrointestinal disorders.
India's drug regulator is cracking down on GLP-1 weight loss drugs due to improper sales and promotions. Inspections across 49 entities revealed violations, leading to notices and potential license cancellations. With semaglutide generics now available post-patent expiry, authorities emphasize prescription-only use by specialists.
India's DCGI is cracking down harder on the unauthorized sale of GLP-1 weight-loss drugs amid rising generic variants. Inspections at online pharmacies, wholesalers, and clinics aim to prevent misuse that could lead to serious health risks. Patients must seek prescriptions only from qualified endocrinologists or specialists.
